Evidence map›Paper›PMID 42257528›Full record

Trial reportMycoses2026

Efficacy Evaluation of Luliconazole-Loaded Nanostructured Lipid Carriers in Treatment-Resistant Dermatophytosis: A Randomized Clinical Trial.

Robab Ebrahimi Barogh, Seyed Ali Jeddi, Ghasem Rahmatpour Rokni, Hossein Mohammad Taghi Fam, Abbas Raeisabadi, Zahra Yahyazadeh, Seyyed Mobin Rahimnia, Pedram Ebrahimnejad, Eisa Nazar, Nasim Gholizadeh and 9 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Robab Ebrahimi BaroghDepartment of Medical Microbiology, Immunology, Parasitology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Seyed Ali JeddiStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Ghasem Rahmatpour RokniDepartment of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Hossein Mohammad Taghi FamStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Abbas RaeisabadiStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Zahra YahyazadehStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Seyyed Mobin RahimniaPharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0003-1499-7668
Pedram EbrahimnejadPharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Eisa NazarPsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-2860-6034
Nasim GholizadehDepartment of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-7234-270X
Iman HaghaniDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-9723-7618
Mohsen NosratabadiDepartment of Laboratory Sciences, Sirjan School of Medical Sciences, Sirjan, Iran.ORCID https://orcid.org/0000-0002-2960-7485
Armaghan KazeminejadDepartment of Dermatology, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-3870-0382
Javad JavidniaDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-9336-2518
Mohammad Taghi HedayatiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-6415-4648
Jacques F MeisDepartment of Medical Microbiology, Radboudumc and Centre for Expertise in Mycology, Radboudumc/CWZ, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0003-3253-6080
Ahmed Al-HarrasiNatural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.ORCID https://orcid.org/0000-0002-0815-5942
Mahdi AbastabarDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-0016-2849
Abdullah M S Al-HatmiNatural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.

Funding

Invasive Fungi Research Center, Mazandaran University of Medical Sciences 20072
6 · The paper itself

Abstract

backgroundDermatophytosis is a common superficial fungal infection that is increasingly complicated by terbinafine (TRB)-resistant strains, especially Trichophyton indotineae. Conventional antifungals often show limited efficacy against resistant isolates, highlighting the need for novel treatments. This study evaluated the efficacy and safety of nanostructured lipid carrier-loaded luliconazole (NLC-LCZ) gel in TRB-resistant dermatophytosis. MATERIALS AND

methodsIn a randomized, clinical trial conducted at Touba Specialty Clinic, Sari, Iran, forty-eight adults with confirmed TRB-resistant dermatophytosis were assigned to oral itraconazole (ITZ), topical luliconazole, NLC-LCZ gel, or ITZ + NLC-LCZ gel for 4 weeks (n = 12 each). The primary endpoint was complete recovery (clinical and mycological), while secondary endpoints included lesion size, itch, inflammation, Dermatology Life Quality Index (DLQI), and safety.

resultsComplete recovery occurred in 83.3% of ITZ + NLC-LCZ, 75% of NLC-LCZ, 58.3% of LCZ, and 0% of ITZ alone. LCZ and NLC-LCZ had lower MIC

conclusionsThese findings indicate that NLC-LCZ enhanced antifungal efficacy and quality of life in TRB-resistant dermatophytosis, and that combination therapy with ITZ + NLC-LCZ yielded the highest recovery, representing a promising strategy against resistant infections.

Indexed as

Antifungal AgentsDrug CarriersImidazolesNanostructuresTineaAdministration, TopicalAdultAgedDrug Resistance, FungalFemaleHumansIranItraconazoleLipidsMaleMicrobial Sensitivity TestsAntifungal AgentsDrug CarriersImidazolesItraconazoleLipidsluliconazoleTerbinafineantifungal resistanceclinical trialdermatophytosisluliconazolenanostructured lipid carrierstrichophyton indotineae

Identifiers

PMID42257528
PMCPMC13245194

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.